Advances in Industrial Engineering

Advances in Industrial Engineering

Dynamic Analysis of Immune System and Cancer Cell Interactions with an Emphasis on Optimizing Therapeutic Approaches

Document Type : Research Paper

Authors
1 Ph.D. Student in Industrial Engineering, University of Kurdistan, Kurdistan, Iran.
2 Associate Professor, Department of Industrial Engineering, University of Kurdistan, Kurdistan, Iran.
3 Associate Professor, Department of Industrial Engineering, Arak University, Arak, Iran.
4 Associate Professor, Department of Electrical Engineering, University of Kurdistan, Kurdistan, Iran.
Abstract
Cancer is a complex and dynamic disease capable of rapidly spreading throughout the body and impairing the immune system. Although immune cells can directly attack tumor cells or activate other components of the immune response, their activity alone is insufficient to achieve complete tumor eradication. Consequently, from a healthcare systems engineering perspective, optimized treatment planning and scheduling are essential to maximize clinical efficacy and resource efficiency. This study employed MATLAB Simulink simulations to model the system dynamics and investigate the effects of chemotherapy and immunotherapy, both individually and in combination, on cancer and immune cells. Cellular population dynamics were first analyzed in the absence of treatment, followed by separate and combined evaluations of each therapy, with particular attention to cellular interactions and cancer cell drug resistance. This approach enables a systematic evaluation of treatment as a multi-objective optimization problem, balancing tumor clearance and immune preservation. The findings revealed that in patients with small initial tumor size and robust immune function, the immune system alone is capable of eliminating cancer cells without therapeutic intervention. However, in patients with large initial tumor size, the combined application of chemotherapy and immunotherapy was predicted to be effective, achieving complete tumor clearance within 38 days while preserving overall health. Collectively, the simulation results suggest that combined chemo-immunotherapy, especially when the sequence of administration is carefully considered, is predicted to be the most effective strategy among the tested protocols and may serve as a model‑based decision support tool for personalized healthcare management, pending prospective clinical validation.
Keywords
Subjects

1.   Tomasetti, C., et al., Only three driver gene mutations are required for the development of lung and colorectal cancers. Proceedings of the National Academy of Sciences, 2015. 112(1): p. 118-123. https://doi.org/10.1073/pnas.1421839112
2.   Vanneman, M. and G. Dranoff, Combining immunotherapy and targeted therapies in cancer treatment. Nature reviews cancer, 2012. 12(4): p. 237-251. https://doi.org/10.1038/nrc3237
3.   Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. cell, 2011. 144(5): p. 646-674. https://doi.org/10.1016/j.cell.2011.02.013
4.   Galluzzi, L., et al., Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer cell, 2015. 28(6): p. 690-714. https://doi.org/10.1016/j.ccell.2015.10.012
5.   Duan, C., et al., Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine & Pharmacotherapy, 2023. 162: p. 114643. https://doi.org/10.1016/j.biopha.2023.114643
6.   Vafaei, S., et al., Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022. 22(1): p. 2. https://doi.org/10.1186/s12935-021-02407-8
7.   Lahiri, A., et al., Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular cancer, 2023. 22(1): p. 40. https://doi.org/10.1186/s12943-023-01740-y
8.   Mukherjee, O., et al., Role of chemotherapeutic drugs in immunomodulation of cancer. Current research in immunology, 2023. 4: p. 100068. https://doi.org/10.1016/j.crimmu.2023.100068
9.   Kirschner, D. and J.C. Panetta, Modeling immunotherapy of the tumor–immune interaction. Journal of mathematical biology, 1998. 37(3): p. 235-252. https://doi.org/10.1007/s002850050127
10. Sudhakar, A., History of cancer, ancient and modern treatment methods. Cancer Science & Therapy, 2009. 1(02): p. i-iv. https://doi.org/10.4172/1948-5956.100000e2
11. Cai, M., et al., Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resistance Updates, 2023. 68: p. 100962. https://doi.org/10.1016/j.drup.2023.100962
12. Khan, S.U., et al., Unveiling the mechanisms and challenges of cancer drug resistance. Cell Communication and Signaling, 2024. 22(1): p. 109. https://doi.org/10.1186/s12964-023-01302-1
13. Zhang, M., et al., Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Molecular cancer, 2025. 24(1): p. 136. https://doi.org/10.1186/s12943-025-02305-x
14. Shu, Y., et al., Mathematical modeling and bifurcation analysis of pro-and anti-tumor macrophages. Applied mathematical modelling, 2020. 88: p. 758-773. https://doi.org/10.1016/j.apm.2020.06.042
15. Pang, L., et al., Mathematical modeling and analysis of tumor-volume variation during radiotherapy. Applied Mathematical Modelling, 2021. 89: p. 1074-1089. https://doi.org/10.1016/j.apm.2020.07.028
16. Ghaffari Laleh, N., et al., Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS computational biology, 2022. 18(2): p. e1009822. https://doi.org/10.1371/journal.pcbi.1009822
17. Sung, P.W., et al., Mathematical modeling to simulate the effect of adding radiation therapy to immunotherapy and application to hepatocellular carcinoma. International Journal of Radiation Oncology* Biology* Physics, 2022. 112(4): p. 1055-1062. https://doi.org/10.1016/j.ijrobp.2021.11.008
18. Kim, Y., et al., A mathematical model for predicting patient responses to combined radiotherapy with CTLA-4 immune checkpoint inhibitors. Cells, 2023. 12(9): p. 1305. https://doi.org/10.3390/cells12091305
19. Bitsouni, V. and V. Tsilidis, Mathematical modeling of tumor-immune system interactions: the effect of rituximab on breast cancer immune response. Journal of Theoretical Biology, 2022. 539: p. 111001. https://doi.org/10.1016/j.jtbi.2021.111001
20. Al-Haideri, M., et al., CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer cell international, 2022. 22(1): p. 365. https://doi.org/10.1186/s12935-022-02778-6
21. Mahasa, K.J., et al., A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept. Mathematical Biosciences and Engineering, 2022. 19(5): p. 4429-4457. https://doi.org/10.3934/mbe.2022205
22. Shariatpanahi, S.P., et al., Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies. Journal of theoretical biology, 2018. 442: p. 1-10. https://doi.org/10.1016/j.jtbi.2018.01.006
23. Owens, K. and I. Bozic, Modeling CAR T-cell therapy with patient preconditioning. Bulletin of Mathematical Biology, 2021. 83(5): p. 42. https://doi.org/10.1007/s11538-021-00869-5
24. de Pillis, L.G., W. Gu, and A.E. Radunskaya, Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. Journal of theoretical biology, 2006. 238(4): p. 841-862. https://doi.org/10.1016/j.jtbi.2005.06.037
25. Van Eijk, M., J.H. Beijnen, and A.D. Huitema, Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors. Anti-Cancer Drugs, 2023. 34(2): p. 281-289. https://doi.org/10.1097/CAD.0000000000001426